Merus Culture d’entreprise

Mr. John J. Crowley has been the Chief Financial Officer and Executive Vice President of Merus B.V., since November 3, 2016. Mr. Crowley leads Merus' finance function and has over 20 years of global biotechnology financial and operational experience. Mr. Crowley served as Chief Accounting Officer, Corporate Senior Vice President and Corporate Controller of Charles River Laboratories International, Inc. since September 30, 2013 until October 31, 2016. Mr. was responsible for providing strategic guidance to the finance groups, including directing the corporate accounting function and practices, maintaining its fiscal records and preparing its financial reports. Mr. Crowley served as Vice President, Chief Accounting Officer & Corporate Controller of Ironwood Pharmaceuticals. He held senior corporate finance positions at Vertex Pharmaceuticals where he successfully managed and directed all areas of technical accounting. He held senior corporate finance positions at Sunovian Pharmaceuticals, Inc. Mr. Crowley is a Certified Public Accountant and graduated Summa Cum Laude from Babson College with B.S. degrees in both Economics and Accountancy.

Mr. Hui Liu, Ph.D. has been the Chief Business Officer and Executive Vice President of Merus B.V since December 16, 2015. Mr. Liu joins Merus from Novartis Oncology, where he headed global business development and licensing efforts. He has extensive experience in strategic business development on a global scale. Mr. Liu's broad deal experience, including those in the immuno-oncology field through recent deals at Novartis Oncology. Prior to Novartis, Mr. Liu was with Pfizer as a senior member of its business development team. Mr. Liu also worked at Goldman Sachs and Citigroup as an investment banker. Mr. Liu earned his Ph.D. in Molecular Biology and MBA in Finance from the University of Michigan and his Bachelor of Science in Biology from Peking University.

Dr. L. Andres Sirulnik, M.D., Ph.D. has been Chief Medical Officer and Senior Vice President of Merus B.V. since October 26, 2016. Dr. Sirulnik is responsible for leading Merus's global clinical development strategy and clinical operations. He held numerous positions of increasing responsibility at Novartis, most recently serving as Vice President and Senior Global Clinical Program Head where he oversaw the clinical strategy for the immune-oncology portfolio. Dr. Sirulnik served as attending physician at the Dana-Farber Cancer Institute and Brigham and Women's Hospital and was a fellow in Hematology/Oncology at Mount Sinai Health System in New York City. Dr. Sirulnik completed his medical residency at North Shore-Long Island Jewish (LIJ) Health System and conducted post doctorate work at Columbia University in New York City. He received his PhD in Medicine and Molecular Biology from King's College, University of Cambridge in England and his MD from Universidad de Buenos Aires in Argentina.

Mr. Lex Bakker Ph.D. serves as CDO and Senior Vice President of Merus B.V. Prior to joining Merus, Mr. Bakker worked at biotechnology company Crucell where he directed the preclinical and clinical develop. Mr. Bakker holds a Ph.D in Tumor Immunology from the University of Nijmegen and was a postdoctoral fellow at the DNAX Research Institute (Palo Alto, CA).

Dr. Ellen Broug, Ph.d has been Head of IP and Secretary at Merus Biopharmaceuticals B.V. since May 2010. Dr. Broug joined ABN AMRO Capital in September 2004 as an Analyst. She focuses on investments in life sciences sector. She served as an Executive of Genmab A/S. She served as Director of Alliance Management at PanGenetics B.V. and served various positions within the Dutch biotechnology arena, including Associate Director at ABN AMRO Capital Life Sciences (now Forbion Capital Partners), Head of Scientific Documentation & Target Evaluation at Genmab and Head of IP at Agamyxis (Hubrecht Institute). In 2001, she joined Genmab B.V. in Utrecht, where she set up the department of Scientific Documentation and played an active role in business development activities, including evaluation of potential new targets for therapeutic antibodies to increase Genmab's pipeline. She became a postdoctoral researcher at the Dept. Surgery, division Surgical Oncology, AZVU, Amsterdam where her research involved different immunotherapeutic approaches for the prevention of liver metastases after surgical excision of primary colorectal carcinoma, including dendritic cell vaccination, gene therapy, and the use of bispecific antibodies. Dr. Broug was trained as a Medical Biologist (University of Leiden). She has a Ph.D. at the Medical Faculty of the Free University in Amsterdam where she studied the neuroendocrine regulation of pulmonary immune responses.

Jillian Connell serves as the VP, Investor Relations and Corporate Communications for Merus N.V.. Jillian started at Merus N.V. in September of 2018. Jillian is based in the Greater Boston Area.

Jeremy Ahouse serves as the VP & Head of Alliance Management for Merus. Jeremy started at Merus in May of 2017. Jeremy is based in the Greater Boston Area.

Agnieszka Cieplinska serves as the VP, Corporate Controller for Merus N.V.. Agnieszka started at Merus N.V. in August of 2018. Agnieszka is based in the Greater Boston Area.